Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
about
Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsPharmacology of polymyxins: new insights into an 'old' class of antibiotics.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rodsAnthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiClinical implications of antibiotic pharmacokinetic principles in the critically ill.Adverse reactions associated with systemic polymyxin therapy.To B or not to B, that is the question: is it time to replace colistin with polymyxin B?Polymyxin B versus colistin: an update.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins.Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategiesColistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients.Critical Need for Clarity in Polymyxin B DosingPolymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
P2860
Q28082546-C4B44945-3449-4AFC-855B-96432D136C3CQ34346283-59BA30D1-233B-4207-9C6F-0F93F2A7B988Q36158501-E2B2BB7F-622C-43B8-AE81-F3C6ED37371AQ37014270-01F7BDD1-6DD1-4703-9F58-74CED7E8E941Q37023206-C7DA63ED-B90F-4E09-8A24-76D6BF9728ECQ38138835-E93CCBE3-8E1E-4A7F-8794-53B0F8553EDCQ38255373-3644B2F9-F404-44F5-81A4-BDD83D56FF9FQ38262873-0318D9DB-4E34-4A3A-A29F-EF44F1D3514FQ38613051-610877FF-FCDB-4B2A-B7A6-B7A73E849716Q38664871-7A529B0F-978A-4B09-9281-4A35ABF8DE5AQ38944862-9BAE1839-5AD1-4C4B-8D16-1A1E2F5B8A2FQ40195691-EF7E8B80-4CB3-4F70-BD3A-F1986D7D1C56Q40587067-11A18681-87CA-4599-B688-FE93B386D1C8Q40719307-8D0B2ABC-F0CD-4377-ABDC-EB499D623F5FQ41695443-7DD8105C-6A48-4C21-839A-D6EAD5371FF4Q42199910-33BC3B11-6C91-4400-A47E-BE3019676B7CQ42358815-F7CE9797-C1AD-465D-B31D-788157FA983CQ43607805-DC824C75-D92C-44BF-B340-70438E51F6B5
P2860
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
@en
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
@nl
type
label
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
@en
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
@nl
prefLabel
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
@en
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
@en
P2093
Alan Forrest
Alexandre P Zavascki
Ana M Sandri
Cornelia B Landersdorfer
David Saitovitch
Diego R Falci
Jiping Wang
Jovan Jacob
Micheline G Dalarosa
P2860
P304
P356
10.1093/JAC/DKS437
P407
P577
2012-11-23T00:00:00Z